...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis
【24h】

Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis

机译：新型口服抗凝剂预防血栓栓塞事件的经济评估：成本最小化分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT AND OBJECTIVE: Randomized clinical trials have shown that the new oral anticoagulants have at least similar impact regarding reduction of thromboembolic events, compared with warfarin, with similar or improved safety profiles. There is little data on real costs within clinical practice. Our aim here was to perform economic analysis on these strategies from the perspective of Brazilian society and the public healthcare system. DESIGN AND SETTING: Cost-minimization analysis; anticoagulation clinic of Hospital Municipal Odilon Behrens, Belo Horizonte, MG, Brazil. METHODS: Patients at the anticoagulation clinic were recruited between August and October 2011, with minimum follow-up of four weeks. Operational and non-operational costs were calculated and corrected to 2015. RESULTS: This study included 633 patients (59% women) of median age 62 years (interquartile range ?-49-73). The mean length of follow-up was 64 ?± 28 days. The average cost per patient per month was $ 54.26 (US dollars). Direct costs accounted for 32.5% of the total cost. Of these, 69.5% were related to healthcare professionals. With regards to indirect costs, 52.4% were related to absence from work and 47.6% to transportation. Apixaban, dabigatran and rivaroxaban were being sold to Brazilian public institutions, on average, for $ 49.87, $ 51.40 and $ 52.16 per patient per month, respectively, which was lower than the costs relating to warfarin treatment. CONCLUSION: In the Brazilian context, from the perspective of society and the public healthcare system, the cumulative costs per patient using warfarin with follow-up in anticoagulation clinics is currently higher than the strategy of prescribing the new oral anticoagulants.
机译：背景与目的：随机临床试验表明，与华法林相比，新型口服抗凝剂在减少血栓栓塞事件方面具有至少相似的作用，具有相似或改善的安全性。在临床实践中，关于实际成本的数据很少。我们的目的是从巴西社会和公共医疗体系的角度对这些策略进行经济分析。设计与设置：成本最小化分析;巴西MG贝洛奥里藏特市市政Odilon Behrens医院抗凝诊所。方法：2011年8月至2011年10月在抗凝门诊招募患者，至少随访4周。计算了运营和非运营成本并将其校正至2015年。结果：这项研究纳入了633名患者（59％的女性），中位年龄62岁（四分位间距为-49-73）。平均随访时间为64±±28天。每个患者每月的平均费用为54.26美元。直接费用占总费用的32.5％。其中69.5％与医疗保健专业人员有关。关于间接成本，52.4％与缺勤有关，47.6％与运输有关。阿哌沙班，达比加群和利伐沙班平均以每名患者每月49.87美元，51.40美元和52.16美元的价格出售给巴西公共机构，这低于与华法林治疗相关的费用。结论：在巴西的背景下，从社会和公共卫生系统的角度来看，目前在抗凝门诊中使用华法林进行随访的每位患者的累积费用高于制定新的口服抗凝药的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号